Hydroxycarbamid 1a Pharma

Hydroxycarbamide, the active ingredient in Hydroxycarbamid 1a Pharma, is a ribonucleotide reductase inhibitor presented as a tablet for oral use. It is employed in the management of sickle cell disease, chronic myelogenous leukemia, polycythemia vera and essential thrombocythemia in appropriate patients.

GNH USA supplies Hydroxycarbamid 1a Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to EU Good Manufacturing Practice and provides reliable logistics for global distribution. All shipments meet regulatory requirements and are supported by comprehensive documentation.

Hydroxycarbamide is used in hematologic disorders that involve abnormal cell proliferation.

Sickle cell disease: reduces frequency of painful crises and the need for blood transfusions. Chronic myelogenous leukemia: helps control disease progression and may improve survival. Polycythemia vera: lowers elevated red blood cell mass and helps maintain target hematocrit. Essential thrombocythemia: decreases platelet count and reduces thrombotic risk.

Hydroxycarbamide may cause a range of adverse reactions, varying from mild gastrointestinal symptoms to potentially serious life‑threatening organ toxicity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset that may require anti‑emetic support. - Mouth ulcers or mucositis: painful lesions in the oral cavity that can affect nutrition. - Low white blood cell counts (neutropenia): decreased neutrophils increasing infection risk.

Serious or Rare Side Effects: - Severe bone marrow suppression leading to pancytopenia: marked reduction of all blood cell lines requiring close monitoring. - Renal toxicity with elevated creatinine: impaired kidney function that may necessitate dose adjustment. - Teratogenic effects causing fetal harm: potential birth defects if exposure occurs during pregnancy.

When prescribing hydroxycarbamide, clinicians should observe several precautionary measures to minimize risks.

- Monitor blood counts: perform complete blood count regularly to detect cytopenias early. - Assess renal function: evaluate serum creatinine and adjust dose in impairment. - Evaluate hepatic function: check liver enzymes before initiation and during therapy. - Avoid use in pregnancy unless essential: discuss risks and ensure effective contraception. - Use contraception: both male and female patients should employ reliable methods during treatment and for several months after discontinuation. - Store at room temperature: keep tablets in the original container, protect from moisture and light.

Hydroxycarbamide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant myelosuppressive chemotherapy: may cause profound bone marrow suppression. - Antiretroviral protease inhibitors (e.g., ritonavir): can increase hydroxycarbamide plasma levels. - Allopurinol: may enhance toxicity leading to severe myelosuppression.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal impairment. - Azathioprine: additive immunosuppressive effect requiring blood count monitoring. - Phenytoin: may reduce hydroxycarbamide effectiveness by inducing metabolism. - Live vaccines: diminished immune response, consider timing of vaccination.